| Medscape | Immunotherapy in Cancer: Hits and Misses, but Charging Ahead Medscape AstraZeneca's setback fell closely on the heels of another negative study, this time the Keynote-040 study of pembrolizumab (Ketyruda, Merck) in head and neck cancer. This was a pivotal phase 3 trial, and it failed to show superiority for immunotherapy ... |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vEEata
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,